| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9649352 | MELINTA THERAP | High purity oritavancin and method of producing same |
Jul, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420592 | MELINTA THERAP | Methods of treatment using single doses of oritavancin |
Aug, 2029
(5 years from now) | |
| US9682061 | MELINTA THERAP | Methods of treating bacterial infections using oritavancin |
Apr, 2030
(6 years from now) | |
Kimyrsa is owned by Melinta Therap.
Kimyrsa contains Oritavancin Diphosphate.
Kimyrsa has a total of 3 drug patents out of which 0 drug patents have expired.
Kimyrsa was authorised for market use on 12 March, 2021.
Kimyrsa is available in powder;intravenous dosage forms.
Kimyrsa can be used as treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent.
Drug patent challenges can be filed against Kimyrsa from 07 August, 2023.
The generics of Kimyrsa are possible to be released after 16 July, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 12, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Aug 06, 2024 |
| New Chemical Entity Exclusivity(NCE) | Aug 06, 2019 |
Drugs and Companies using ORITAVANCIN DIPHOSPHATE ingredient
NCE-1 date: 07 August, 2023
Market Authorisation Date: 12 March, 2021
Treatment: Treatment of acute bacterial skin and skin structure infections with a single dose of 1200mg oritavancin or its single dose equivalent
Dosage: POWDER;INTRAVENOUS
KIMYRSA family patents
